Literature DB >> 31228486

Trimerization of dopamine transporter triggered by AIM-100 binding: Molecular mechanism and effect of mutations.

Mary Hongying Cheng1, Luca Ponzoni1, Tatiana Sorkina2, Ji Young Lee1, She Zhang1, Alexander Sorkin2, Ivet Bahar3.   

Abstract

Recent work demonstrated the propensity of dopamine transporters (DATs) to form trimers or higher oligomers, enhanced upon binding a furopyrimidine, AIM-100. AIM-100 binding promotes DAT endocytosis and thereby moderates dopaminergic transmission. Despite the neurobiological significance of these events, the molecular mechanisms that underlie the stabilization of DAT trimer and the key interactions that modulate the trimerization of DAT, and not serotonin transporter SERT, remain unclear. In the present study, we determined three structural models, termed trimer-W238, -C306 and -Y303, for possible trimerization of DATs . To this aim, we used structural data resolved for DAT and its structural homologs that share the LeuT fold, advanced computational modeling and simulations, site-directed mutagenesis experiments and live-cell imaging assays. The models are in accord with the versatility of LeuT fold to stabilize dimeric or higher order constructs. Selected residues show a high propensity to occupy interfacial regions. Among them, D231-W238 in the extracellular loop EL2, including the intersubunit salt-bridge forming pair D231/D232-R237 (not present in SERT) (in trimer-W238), the loop EL3 (trimers-C306 and -Y303), and W497 on the intracellularly exposed IL5 loop (trimer-C306) and its spatial neighbors (e.g. K525) near the C-terminus are computationally predicted and experimentally confirmed to play important roles in enabling the correct folding and/or oligomerization of DATs in the presence of AIM-100. The study suggests the possibility of controlling the effective transport of dopamine by altering the oligomerization state of DAT upon small molecule binding, as a possible intervention strategy to modulate dopaminergic signaling. This article is part of the issue entitled 'Special Issue on Neurotransmitter Transporters'.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Docking and molecular dynamics simulations; Dopamine transporter; Furopyrimidine AIM-100; In silico saturation mutagenesis; Oligomerization; Structural dynamics

Mesh:

Substances:

Year:  2019        PMID: 31228486      PMCID: PMC6917874          DOI: 10.1016/j.neuropharm.2019.107676

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  86 in total

1.  Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action.

Authors:  Stefan Seidel; Ernst A Singer; Herwig Just; Hesso Farhan; Petra Scholze; Oliver Kudlacek; Marion Holy; Karl Koppatz; Peter Krivanek; Michael Freissmuth; Harald H Sitte
Journal:  Mol Pharmacol       Date:  2005-01       Impact factor: 4.436

Review 2.  Neurotransmitter transporters as molecular targets for addictive drugs.

Authors:  S G Amara; M S Sonders
Journal:  Drug Alcohol Depend       Date:  1998 Jun-Jul       Impact factor: 4.492

Review 3.  Structure, dynamics, assembly, and evolution of protein complexes.

Authors:  Joseph A Marsh; Sarah A Teichmann
Journal:  Annu Rev Biochem       Date:  2014-12-08       Impact factor: 23.643

4.  Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities.

Authors:  Juan Zhen; Tamara Antonio; Shu-Yuan Cheng; Solav Ali; Kymry T Jones; Maarten E A Reith
Journal:  J Neurochem       Date:  2015-01-26       Impact factor: 5.372

5.  Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment.

Authors:  H Hastrup; A Karlin; J A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 6.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

7.  Interrelation of dopamine transporter oligomerization and surface presence as studied with mutant transporter proteins and amphetamine.

Authors:  Yan Li; Shu-Yuan Cheng; Nianhang Chen; Maarten E A Reith
Journal:  J Neurochem       Date:  2010-05-18       Impact factor: 5.372

8.  Super-resolution microscopy reveals functional organization of dopamine transporters into cholesterol and neuronal activity-dependent nanodomains.

Authors:  Troels Rahbek-Clemmensen; Matthew D Lycas; Simon Erlendsson; Jacob Eriksen; Mia Apuschkin; Frederik Vilhardt; Trine N Jørgensen; Freja H Hansen; Ulrik Gether
Journal:  Nat Commun       Date:  2017-09-29       Impact factor: 14.919

9.  Small molecule induced oligomerization, clustering and clathrin-independent endocytosis of the dopamine transporter.

Authors:  Tatiana Sorkina; Shiqi Ma; Mads Breum Larsen; Simon C Watkins; Alexander Sorkin
Journal:  Elife       Date:  2018-04-09       Impact factor: 8.140

10.  The Pfam protein families database in 2019.

Authors:  Sara El-Gebali; Jaina Mistry; Alex Bateman; Sean R Eddy; Aurélien Luciani; Simon C Potter; Matloob Qureshi; Lorna J Richardson; Gustavo A Salazar; Alfredo Smart; Erik L L Sonnhammer; Layla Hirsh; Lisanna Paladin; Damiano Piovesan; Silvio C E Tosatto; Robert D Finn
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  2 in total

1.  Dopamine transporter trafficking and Rit2 GTPase: Mechanism of action and in vivo impact.

Authors:  Rita R Fagan; Patrick J Kearney; Carolyn G Sweeney; Dino Luethi; Florianne E Schoot Uiterkamp; Klaus Schicker; Brian S Alejandro; Lauren C O'Connor; Harald H Sitte; Haley E Melikian
Journal:  J Biol Chem       Date:  2020-03-04       Impact factor: 5.157

Review 2.  SLC6 transporter oligomerization.

Authors:  Kumaresan Jayaraman; Anand K Das; Dino Luethi; Dániel Szöllősi; Gerhard J Schütz; Maarten E A Reith; Harald H Sitte; Thomas Stockner
Journal:  J Neurochem       Date:  2020-08-28       Impact factor: 5.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.